Michalowsky Bernhard, Platen Moritz, Bohlken Jens, Kostev Karel
German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany.
Institute for Social Medicine, Occupational Medicine, and Public Health (ISAP) of the Medical Faculty, University of Leipzig, Leipzig, Germany.
J Alzheimers Dis Rep. 2022 Oct 18;6(1):641-650. doi: 10.3233/ADR-220004. eCollection 2022.
Previous studies revealed that low-value medication (LvM), drugs that provide little or no benefit but have the potential to cause harm, are associated with hospitalizations in dementia. Recommended medications, referred to as high-value medication (HvM), can be used alternately. However, the effect of LvM and HvM on hospitalizations is uncertain.
To determine the prevalence of LvM and HvM in hospitalized and non-hospitalized patients living with dementia (PwD) and the odds for hospital referrals in PwD receiving LvM or HvM.
The analysis was based on 47,446 PwD who visited a general practitioner practice between 2017 and 2019. Different guidelines were used to elicit LvM and HvM, resulting in 185 LvM and HvM related recommendations. Of these, 117 recommendations (83 for LvM, 34 for HvM) were categorized into thirteen therapy classes. The association of hospital referrals issued by general practitioners and receiving LvM or HvM was assessed using multiple logistic regression models.
20.4% of PWD received LvM. Most frequently prescribed LvM were non-recommended sedatives and hypnotics, analgesics, and antidepressants. Recommended HvM were 3.4 (69.9%) more frequently prescribed than LvM. Most commonly prescribed HvM were recommended antihypertensives, antiplatelet agents, and antiarrhythmics. Both receiving LvM and receiving HvM were associated with higher odds for hospital referrals. When receiving LvM were compared to HvM, no significant differences could be found in hospital referrals.
LvM is highly prevalent but did not cause more likely hospital referrals than HvM. Further research should focus on acute hospitalizations, not only on planned hospital referrals.
先前的研究表明,低价值药物(LvM),即那些益处极少或没有益处但有潜在危害的药物,与痴呆患者的住院治疗有关。推荐药物,即高价值药物(HvM),可交替使用。然而,低价值药物和高价值药物对住院治疗的影响尚不确定。
确定住院和非住院痴呆患者(PwD)中低价值药物和高价值药物的患病率,以及接受低价值药物或高价值药物的痴呆患者被转诊至医院的几率。
该分析基于2017年至2019年间就诊于全科医生诊所的47446例痴呆患者。使用不同的指南来确定低价值药物和高价值药物,得出了185条与低价值药物和高价值药物相关的推荐。其中,117条推荐(低价值药物83条,高价值药物34条)被归类为13个治疗类别。使用多元逻辑回归模型评估全科医生发出的医院转诊与接受低价值药物或高价值药物之间的关联。
20.4%的痴呆患者接受了低价值药物。最常开具的低价值药物是未被推荐的镇静催眠药、镇痛药和抗抑郁药。推荐的高价值药物的处方频率比低价值药物高3.4倍(69.9%)。最常开具的高价值药物是推荐的抗高血压药、抗血小板药和抗心律失常药。接受低价值药物和接受高价值药物都与更高的医院转诊几率相关。将接受低价值药物与接受高价值药物进行比较时,在医院转诊方面未发现显著差异。
低价值药物非常普遍,但与高价值药物相比,其导致医院转诊的可能性并不更高。进一步的研究应关注急性住院治疗,而不仅仅是计划性的医院转诊。